Vogenx Inc (VOGX)
NASDAQ · Manufacturing · Pharmaceutical preparations
$23.04−$1.16 (−4.79%) on the dayAs of the close; data may be delayed.
VOGX price, last 12 months
Key stats
- Previous close
- $24.20
- Open
- $23.72
- Day range
- $22.08 – $24.36
- 52-week range
- $12.95 – $38.41
- Volume
- 29.2K
- Avg volume (20 days)
- 150.8K
- Market cap
- $337.7M
Performance
1W−29.1%
1M−29.9%
3M—
6M—
YTD—
1Y—
Technicals and fundamentals
About Vogenx Inc
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $337.7M